2-(cyclohexylmethyl)phenol | 5899-19-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 2-(cyclohexylmethyl)phenol
• 英文别名: 2-Hexahydrobenzyl-phenol
• CAS: 5899-19-4
• 化学式: C₁₃H₁₈O
• 分子量: 190.285
• InChiKey: GMHGILBQRWZITO-UHFFFAOYSA-N

物化性质

• 熔点：
  65-66 °C
• 沸点：
  128-129 °C(Press: 10 Torr)
• 密度：
  1.038±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P330,P363,P501
• 危险性描述：
  H302,H312,H332

反应信息

• 作为反应物：
  描述：

  2-(cyclohexylmethyl)phenol 在 四丁基溴化铵 、 sodium hydride 作用下， 以 四氢呋喃 、 氯仿 为溶剂， 反应 1.5h， 生成 ethyl 2-(4-bromo-2-(cyclohexylmethyl)phenoxy)acetate
  参考文献：
  名称：

  4,4′-Unsymmetrically substituted 3,3′-biphenyl alpha helical proteomimetics as potential coactivator binding inhibitors

  摘要：

  A series of unsymmetrically substituted biphenyl compounds was designed as alpha helical proteomimetics with the aim of inhibiting the binding of coactivator proteins to the nuclear hormone receptor coactivator binding domain. These compounds were synthesized in good overall yields in seven steps starting from 2-bromoanisole. The final products were evaluated using cotransfection reporter gene assays and mammalian two-hybrid competitive inhibition assays to demonstrate their effectiveness as competitive binding inhibitors. The results from this study indicate that these proteomimetics possess the ability to inhibit coactivator-receptor interactions, but via a mixed mode of inhibition. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.10.051
• 作为产物：
  描述：

  cyclohexyl(2-hydroxyphenyl)methanone 在 盐酸 、 mercury dichloride 、 锌 作用下， 以 甲苯 为溶剂， 反应 3.0h， 以70%的产率得到2-(cyclohexylmethyl)phenol
  参考文献：
  名称：

  Photochemistry of o-allylphenol. Identification of the minor products and new mechanistic proposals

  摘要：

  The photochemistry of o-allylphenol (1) in cyclohexane has been reinvestigated. Besides the previously reported cyclic ethers 2 and 3, seven additional minor photoproducts have been detected. Spectroscopic methods, coupled with independent synthesis, have allowed their identification as 2-methylbenzofuran (5), o-propylphenol (8), the epoxide 4, the dihydroxy compound 9, the cyclohexyl ether 6, o-(cyclohexylmethyl)phenol (10), and the dimer 7. Their formation is rationalized through new mechanistic pathways, which involve initial intermolecular electron and/or proton transfer between two molecules of o-allylphenol, as well as di-pi-methane rearrangement. Key intermediates appear to be radical V, carbenium ion IX, and carbene XI. This is supported by photolysis of o-allylphenyl acetate (I 1), which leads to the formation of a radical pair, followed by in cage recombination to the photo-Fries products 12 and 13 or, alternatively, diffusion of the radicals out of the solvent cage to afford the minor products 2, 5, and 6, identical to those obtained by photolysis of 1.

  DOI：

  10.1021/jo00064a016

文献信息

• Metal cation-exchanged montmorillonite (Mn+-mont)-catalysed aromatic alkylation with aldehydes and ketones
  作者：Jun-ichi Tateiwa、Ei Hayama、Takahiro Nishimura、Sakae Uemura

  DOI：10.1039/a701744h

  日期：——

  The alkylation of aromatic compounds with aldehydes and ketones in the presence of a variety of metal cation-exchanged montmorillonites (Mn+-mont; Mn+ = Zr4+, Al3+, Fe3+, Zn2+, H+, Na+) has been investigated. Al3+- and Zr4+-Monts are revealed to be effective as catalysts, while no reaction takes place with Na+-mont. Al3+-Mont-catalysed alkylation of phenol with several aldehydes produces mainly or almost solely the corresponding gem-bis(hydroxyphenyl)alkanes (bisphenols) in good yields, while that with several ketones affords selectively the corresponding alkylphenols in moderate to good yields. The alkylation always occurs at the carbonyl carbon without any skeletal rearrangement and the kind of products depends much on the steric hindrance of an electrophilic intermediary carbocation. The alkylation of anisole, veratrole and p-cresol proceeds well, while that of toluene, benzene, chlorobenzene and nitrobenzene scarcely occurs.

  在各种金属阳离子交换的蒙脱石（Mn+-mont；Mn+ = Zr4+、Al3+、Fe3+、Zn2+、H+、Na+）存在下，研究了芳香化合物与醛和酮的烷基化反应。发现Al3+和Zr4+蒙脱石是有效的催化剂，而Na+蒙脱石则不发生反应。由Al3+蒙脱石催化的苯酚与几种醛的烷基化反应主要或几乎只生成了相应的双（羟苯基）烷烃（双酚），产率良好；而与几种酮的烷基化反应则选择性地生成了相应的烷基苯酚，产率适中至良好。烷基化总是发生在羰基碳上，没有骨架重排，产物的类型很大程度上取决于亲电中间体的碳正离子的空间位阻。茴香醚、邻苯二甲醚和对甲酚的烷基化反应良好进行，而甲苯、苯、氯苯和硝基苯的烷基化反应几乎不发生。
• Photoreactions of <i>trans</i>-1-<i>o</i>-Hydroxyphenyl-2-phenylcyclopropane
  作者：Julio Delgado、Amparo Espinós、M. Consuelo Jiménez、Miguel A. Miranda、Heinz D. Roth、Rosa Tormos

  DOI：10.1021/jo981558g

  日期：1999.9.1

  Direct irradiation in methanol produced methanol adducts 8 and 9 instead of 2, 3, 4, or 7. Finally, acetone-sensitized irradiation of trans-1 resulted in geometric isomerization to cis-1; this result can be rationalized via a biradical intermediate.

  在各种实验条件下研究了反式-1-邻羟基苯基-2-苯基环丙烷反式-1的光化学。在环己烷中通过石英直接照射主要产生扩环产物：2-苯基-3,4-二氢-2H-苯并吡喃，2，2-苄基-2,3-二氢苯并呋喃，3和1-o-羟基苯基茚满。 4.通过分子内质子转移使主要产物2和3合理化。然而，3的很大一部分是通过对肉桂基苯酚5的开环而形成的。另一种产物邻-（α-环己基甲基）苯酚7暗示了反式-1的断裂和邻羟基苯卡宾的（正式）插入环己烷中。直接在甲醇中辐照可生成甲醇加合物8和9，而不是2、3、4或7。最后，丙酮敏化的trans-1辐照导致几何异构化为cis-1；
• Amino alcohol derivatives or phosphonic acid derivatives and pharmaceutical compositions containing these
  申请人：Nishi Takahide

  公开号：US20050043386A1

  公开（公告）日：2005-02-24

  Amino alcohol compounds and phosphonic acid compounds having excellent immunosuppressive activity, pharmacologically acceptable salts thereof and pharmacologically acceptable esters thereof, and pharmaceutical compositions comprising such compounds, the compounds having the following formula: wherein R 1 and R 2 each represent hydrogen, or a protecting group of the amino group; R 3 represents hydrogen, or a protecting group of the hydroxyl group; R 4 represents a lower alkyl group; n is 1 to 6; X represents oxygen or nitrogen, which is unsubstituted or substituted with a lower alkyl group; Y represents ethylene; Z represents a C 1 -C 10 alkylene; R 5 represents an aryl group; and R 6 and R 7 each represents hydrogen; provided that when R 5 represents hydrogen, then Z represents a group other than a single bond or a straight chain C 1 -C 10 alkylene group.

  具有出色的免疫抑制活性的氨基醇化合物和膦酸化合物，其药理学上可接受的盐和药理学上可接受的酯，以及包含这些化合物的制药组合物，其中化合物具有以下式子：其中R1和R2各代表氢，或氨基保护基；R3代表氢，或羟基保护基；R4代表较低的烷基；n为1至6；X代表氧或氮，未取代或取代为较低的烷基；Y代表乙烯；Z代表C1-C10烷基；R5代表芳基；R6和R7各代表氢；但是当R5代表氢时，Z代表除单键或直链C1-C10烷基组以外的一种基团。
• Amino alcohol compounds
  申请人：Nishi Takahide

  公开号：US20070105933A1

  公开（公告）日：2007-05-10

  A method for the preventing a disease selected from the group consisting of rheumatoid arthritis and psoriasis in a mammal, such as a human, in need thereof, which includes administering to the mammal a pharmaceutically effective amount of a compound of formula (Ia) wherein R 1 and R 2 are each hydrogen; R 3 is hydrogen; R 4 is C 1 -C 2 alkyl; n is 2; X is=N-D, wherein D is hydrogen, C 1 -C 4 alkyl or phenyl; Y is ethylene, ethynylene, —CO—CH 2 or phenylene; Z is ethylene or trimethylene; R 5 is an unsubstituted C 3 -C 10 cycloalkyl, an unsubstituted C 6 -C 10 aryl, or a C 3 -C 10 cycloalkyl or C 6 -C 10 aryl substituted with 1 to 3 substituents selected from the group consisting of halogen, lower alkyl, halogeno lower alkyl and lower alkoxy; and R 6 and R 7 are each hydrogen.

  本发明涉及一种用于预防哺乳动物，例如人类，需要预防风湿性关节炎和银屑病等疾病的方法，包括向哺乳动物内部给予化合物（Ia）的药物有效量，其中R1和R2均为氢; R3为氢; R4为C1-C2烷基; n为2; X为=N-D，其中D为氢、C1-C4烷基或苯基; Y为乙烯基、乙炔基、-CO-CH2或苯基; Z为乙烯基或三亚甲基; R5为未取代的C3-C10环烷基、未取代的C6-C10芳基或取代有1-3个取代基的C3-C10环烷基或C6-C10芳基，所述取代基选自卤素、低碳基、卤代低碳基和低烷氧基的群体; R6和R7均为氢。
• Method for treating a immunology-related disease
  申请人：Nishi Takahide

  公开号：US20090326038A1

  公开（公告）日：2009-12-31

  A method for treating an immunology-related disease. The method involves administering to a mammal in need thereof a pharmaceutically effective amount of an amino acid compound, a pharmacologically acceptable salt thereof or a pharmacologically acceptable ester thereof. The compound has the following formula: , wherein R 1 and R 2 are each hydrogen; R 3 is hydrogen; R 4 is C 1 -C 2 alkyl; n is 2; X is ═N-D, wherein D is hydrogen, C 1 -C 4 alkyl or phenyl; Y is ethylene, ethynylene, —CO—CH 2 or phenylene; Z is ethylene or trimethylene; R 5 is unsubstituted C 3 -C 10 cycloalkyl, unsubstituted C 3 -C 10 aryl, or C 3 -C 10 cycloalkyl or C 6 -C 10 aryl substituted with 1 to 3 substituents selected from the group consisting of halogen, lower alkyl, halogeno lower alkyl and lower alkoxy; and R 6 and R 7 are each hydrogen.

  一种治疗免疫相关疾病的方法。该方法涉及向需要治疗的哺乳动物中注射药物有效量的氨基酸化合物，其药理学上可接受的盐或其药理学上可接受的酯。该化合物具有以下式子：其中R1和R2均为氢；R3为氢；R4为C1-C2烷基；n为2；X为═N-D，其中D为氢、C1-C4烷基或苯基；Y为乙烯、乙炔基、—CO—CH2或苯基；Z为乙烯或三亚甲基；R5为未取代的C3-C10环烷基、未取代的C3-C10芳基或取代有1至3个卤素、低烷基、卤代低烷基和低烷氧基的C3-C10环烷基或C6-C10芳基；R6和R7均为氢。